Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.

@article{Martin2009MinimizingCW,
  title={Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.},
  author={Miguel A. Rios Martin and Francisco J. Esteva and Emilio Alba and Bijoy K. Khandheria and Leopoldo P{\'e}rez-Isla and Jos{\'e} Angel Garc{\'i}a-Saenz and Antonia M{\'a}rquez and Partho P. Sengupta and Jose Luis Zamorano},
  journal={The oncologist},
  year={2009},
  volume={14 1},
  pages={1-11}
}
Numerous clinical studies have demonstrated the therapeutic benefit of trastuzumab in women with breast cancer. However, a small but not insignificant proportion of patients have experienced trastuzumab-associated cardiotoxicity during these trials. This phenomenon is generally characterized by an asymptomatic reduction in left ventricular ejection fraction (LVEF) or, less often, congestive heart failure (CHF). Concomitant anthracycline therapy significantly increases the risk for… CONTINUE READING
50 Citations
51 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin : A retrospective review of the M . D . Anderson experience

  • ET Yeh, AT Tong, DJ Lenihan
  • Cancer
  • 2007

Results of a phase II trial of Herceptin plus Xeloda in patients with previously untreated HER 2 - positive metastatic breast can

  • J Zhu
  • Breast Cancer Res Treat
  • 2007

Similar Papers

Loading similar papers…